Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – Should You Sell?

Capricor Therapeutics, Inc. (NASDAQ:CAPR)’s share price gapped down prior to trading on Thursday . The stock had previously closed at $29.96, but opened at $28.25. Capricor Therapeutics shares last traded at $26.6610, with a volume of 2,575,009 shares trading hands.

Wall Street Analysts Forecast Growth

CAPR has been the topic of several research reports. Industrial Alliance Securities set a $48.00 target price on Capricor Therapeutics in a research note on Wednesday. Maxim Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Thursday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a research report on Wednesday, October 8th. Alliance Global Partners reiterated a “buy” rating on shares of Capricor Therapeutics in a research note on Wednesday. Finally, HC Wainwright increased their price objective on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.30.

Capricor Therapeutics Price Performance

The stock has a market capitalization of $1.14 billion, a P/E ratio of -13.95 and a beta of 0.61. The company’s 50-day simple moving average is $6.82 and its 200-day simple moving average is $8.02.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.54). On average, analysts forecast that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Trading of Capricor Therapeutics

Hedge funds have recently made changes to their positions in the business. Octagon Capital Advisors LP bought a new position in Capricor Therapeutics during the 1st quarter worth $4,270,000. GSA Capital Partners LLP acquired a new position in shares of Capricor Therapeutics in the third quarter valued at about $1,555,000. Two Sigma Investments LP increased its position in Capricor Therapeutics by 128.3% during the third quarter. Two Sigma Investments LP now owns 355,796 shares of the biotechnology company’s stock worth $2,565,000 after acquiring an additional 199,959 shares during the period. Raymond James Financial Inc. raised its stake in Capricor Therapeutics by 1,629.9% in the 3rd quarter. Raymond James Financial Inc. now owns 191,292 shares of the biotechnology company’s stock worth $1,379,000 after purchasing an additional 180,234 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in Capricor Therapeutics in the 1st quarter valued at about $1,547,000. 21.68% of the stock is owned by institutional investors and hedge funds.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.